Company

Nacuity Pharmaceuticals, Inc.

Fort Worth biopharmaceutical company developing prescription therapies to halt oxidative stress in retinal and other blinding eye diseases.

About

Nacuity Pharmaceuticals, Inc., founded in 2016 in Fort Worth, US, develops therapies for retinal diseases. Its targeted prescription therapies address conditions including retinitis pigmentosa, cataract and cystinosis, and are mainly marketed in the United States. The company received USD 16.5 mn in Series B funding on June 15, 2022, led by Foundation Fighting Blindness, with Maxim Group and Retinal Degeneration Fund also investing. Founder Halden Conner has a background in pharmaceutical development.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in